Lummy(SZ:300006) Mei Ri Jing Ji Xin Wen·2025-12-29 09:04Group 1 - The core point of the article is that Laimei Pharmaceutical (SZ 300006) held its 49th board meeting on December 29, 2025, via telecommunication to discuss the performance assessment plan for the leadership team in 2024 [1] - For the year 2024, Laimei Pharmaceutical's revenue composition is as follows: 84.09% from pharmaceutical manufacturing, 13.06% from pharmaceutical distribution, 1.64% from other businesses, and 1.21% from service income [1] - As of the report date, Laimei Pharmaceutical has a market capitalization of 5.6 billion yuan [1] Group 2 - The article also mentions a significant event involving Moutai distributors, where over 2,000 attendees gathered for a conference to discuss major changes related to Moutai's pricing and distribution strategies [1] - Chairman Chen Hua emphasized that distributors can no longer rely on passive income [1]